Actively Recruiting
Phase 1 Study of Pomalidomide with Dose-Adjusted EPOCH Chemotherapy With or Without Rituximab for High-Risk HIV-Associated B-Cell Lymphomas
Led by National Cancer Institute (NCI) · Updated on 2026-08-25
25
Participants Needed
1
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
This research focuses on people living with HIV who have a type of cancer called HIV-associated B-cell non-Hodgkin lymphoma NHL, which is more common and may behave differently in people with HIV. The study aims to evaluate the safety and best dose of a drug called pomalidomide combined with chemotherapy, with or without the addition of rituximab, specifically in adults with high-risk HIV-associated NHL. This is a phase 1 trial designed to find safe and tolerable treatment options for this underserved population. Participants will receive up to six treatment cycles. The first cycle lasts 26 days and includes taking pomalidomide by mouth for 10 days, starting five days before chemotherapy infusions. Chemotherapy drugs will be given through a vein over several days, and some participants with certain tumor types will also receive rituximab. Cycles two through six each last 21 days, with pomalidomide given orally for the first 10 days and chemotherapy repeated starting on day 1. The study includes a dose escalation phase to find the maximum tolerated dose of pomalidomide. Participants will undergo screening involving physical exams, blood and urine tests, heart function assessments, and imaging scans. Tissue samples from tumors will be reviewed, and additional biopsies may be required. During treatment, screening tests will be repeated at study visits. After treatment, participants will have follow-up visits for up to four years to monitor their health and response. Researchers will measure safety, tolerability, progression-free survival, and response to treatment throughout the study period.
CONDITIONS
Brief Title
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Research Team
I
Irene B Ekwede, R.N.
R
Ramya M Ramaswami, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here